• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsProfilesView

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Capivasertib, an AKT kinase inhibitor, as monotherapy or in combination with fulvestrant in patients with AKT1 (E17K)-mutant, ER-positive metastatic breast cancer

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Smyth, LM
    Tamura, K
    Oliveira, M
    Ciruelos, EM
    Mayer, IA
    Sablin, MP
    Biganzoli, L
    Ambrose, HJ
    Ashton, Jack
    Barnicle, A
    Cashell, DD
    Corcoran, C
    de Bruin, EC
    Foxley, A
    Hauser, J
    Lindemann, JPO
    Maudsley, R
    McEwen, R
    Moschetta, M
    Pass, M
    Rowlands, V
    Schiavon, G
    Banerji, U
    Scaltriti, M
    Taylor, BS
    Chandarlapaty, S
    Baselga, J
    Hyman, DM
    Show allShow less
    Affiliation
    Medicine, Memorial Sloan Kettering Cancer Center
    Issue Date
    2020
    
    Metadata
    Show full item record
    Citation
    Smyth LM, Tamura K, Oliveira M, Ciruelos EM, Mayer IA, Sablin MP, et al. Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination With Fulvestrant in Patients With AKT1 (E17K)-Mutant, ER-Positive Metastatic Breast Cancer. Clin Cancer Res. 2020.
    Journal
    Clinical Cancer Research
    URI
    http://hdl.handle.net/10541/622995
    DOI
    10.1158/1078-0432.ccr-19-3953
    PubMed ID
    32312891
    Additional Links
    https://dx.doi.org/ 10.1158/1078-0432.ccr-19-3953
    Type
    Article
    Language
    en
    ae974a485f413a2113503eed53cd6c53
    10.1158/1078-0432.ccr-19-3953
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • Capivasertib plus fulvestrant in patients with HR-positive/HER2-negative advanced breast cancer: phase 3 CAPItello-291 study extended Chinese cohort.
    • Authors: Hu X, Zhang Q, Sun T, Xiong H, Li W, Teng Y, Lu YS, Tseng LM, Yan M, Li H, Pang D, -Chen SC, Chen W, Jiang O, Wang J, Wu X, Wang X, Zang A, Wang X, Collins JM, Fan E, Jiang L, Zeng X, Turner NC
    • Issue date: 2025 May 9
    • US Food and Drug Administration Approval Summary: Capivasertib With Fulvestrant for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced or Metastatic Breast Cancer With PIK3CA/AKT1/PTEN Alterations.
    • Authors: Dilawari A, Buturla J, Osgood C, Gao X, Chen W, Ricks TK, Schaefer T, Avasarala S, Reyes Turcu F, Pathak A, Kalavar S, Bhatnagar V, Collazo J, Rahman NA, Mixter B, Tang S, Pazdur R, Kluetz P, Amiri-Kordestani L
    • Issue date: 2024 Dec
    • Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial.
    • Authors: Howell SJ, Casbard A, Carucci M, Ingarfield K, Butler R, Morgan S, Meissner M, Bale C, Bezecny P, Moon S, Twelves C, Venkitaraman R, Waters S, de Bruin EC, Schiavon G, Foxley A, Jones RH
    • Issue date: 2022 Jul
    • BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population.
    • Authors: Turner NC, Alarcón E, Armstrong AC, Philco M, López Chuken YA, Sablin MP, Tamura K, Gómez Villanueva A, Pérez-Fidalgo JA, Cheung SYA, Corcoran C, Cullberg M, Davies BR, de Bruin EC, Foxley A, Lindemann JPO, Maudsley R, Moschetta M, Outhwaite E, Pass M, Rugman P, Schiavon G, Oliveira M
    • Issue date: 2019 May 1
    • Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor: NCI-MATCH Subprotocol EAY131-Y Nonrandomized Trial.
    • Authors: Kalinsky K, Hong F, McCourt CK, Sachdev JC, Mitchell EP, Zwiebel JA, Doyle LA, McShane LM, Li S, Gray RJ, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Conley BA, O'Dwyer PJ, Harris LN, Arteaga CL, Chen AP, Flaherty KT
    • Issue date: 2021 Feb 1
    DSpace software (copyright © 2002 - 2025)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.